# Diagnostics

# Key launches 2019

| | Area | Product | Description | Market[1] |
|---|---|---|---|---|
| Instruments/ Devices | Workflow | cobas prime | Pre-analytical platform to support cobas 6800/8800 | CE/US |
| Tests/ Assays | Coagulation | Protein C Chrom | Quantitative determination of protein C in citrated plasma on cobas t 511 / t 711 analyzers | CE |
| | Microbiology | cobas TV/MG | High volume solution for TV/MG testing; dual-target test with ability to test with CT/NG from the same specimen during the same run | US ✓ |
| | | cobas vivoDx MRSA | Live cell assay for prevention and control of MRSA infections | CE ✓ |
| | Tissue Dx | VENTANA HER2 Dual ISH | Fully automated, brightfield ISH assay to determine eligibility for HER2 targeted therapy | CE ✓ |
| Software | Central Laboratory | cobas Infinity Central Lab 3.0 | One global laboratory middleware solution realizing a very high degree of integration in the laboratory | WW ✓ |
| | Tissue Dx | Algorithm - Breast Panel | Whole slide analysis image analysis algorithm (HER2, ER, PR, Ki-67) | CE |
| | | Algorithm - PD-L1 Lung | Whole slide analysis image analysis algorithm (SP263) | CE |
| | Sequencing | NAVIFY Mutation Profiler | Software as a medical device for annotating, variant classification, clinical interpretation and reporting from comprehensive genomic profile testing | CE ✓ US[2] |
| | | NAVIFY Therapy Matcher | Informing on treatment options based on local drug labels, medical guidelines and clinical trial outcomes | CE ✓ US[2] |
| | Decision Support | NAVIFY Tumor Board V2 | Integrating a GEHC DICOM imaging viewer into the Tumor Board to support the radiologist | WW ✓ |
| | | NAVIFY Oncology Workflow V1 | Integration of patient's longitudinal history, diagnosis, and treatment planning by leveraging relevant guidelines | WW |
| | Diabetes Care | Accu-Chek Sugar View 2.0 (non-ISO) | For non-insulin dependent T2 PwDs, allowing for meter-free blood glucose monitoring using Accu-Chek Active test strips and a smartphone camera | CE |

[1] CE: European Conformity, US: FDA approval, WW: Worldwide; GEHC DICOM: GE Healthcare Digital Imaging and Communications in Medicine; T2: Type II Diabetes; PwDs: People with Diabetes
[2] NAVIFY Mutation Profiler and Therapy Matcher received CE mark; US approval expected by end of 2019.

*Doing now what patients need next*